Description General description A cell-permeable peptide aldehyde that acts as a potent and reversible inhibitor of calpain (IC50 = 7.5 nM for µ-calpain and 78 nM for m-calpain). Also potently inhibits cathepsin B (IC50 = 15 nM) and cathepsin L (IC50 = 1.6 nM). Reduces βFGF-induced angiogenesis in rat cornea and prevents selenite cataract formation in rats. Reduces A23187-induced nuclear opacity and proteolysis of crystallins and α-spectrin in cultured rat lenses. A potent, cell-permeable, reversible inhibitor of calpain (IC50 = 7.5 nM for µ-calpain and 78 nM for m-calpain). Also potently inhibits cathepsin B (IC50 = 15 nM) and L (IC50 = 1.6 nM). Reduces bFGF-induced angiogenesis in rat cornea and prevents selenite cataract formation. Reduces A23187-induced nuclear opacity and proteolysis of crystallins and α-spectrin in cultured lenses. Packaging 1, 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target µ-calpain Product does not compete with ATP. Reversible: yes Target IC50: 7.5 nM for µ-calpain and 78 nM for m-calpain; 15 nM and 1.6 nM against cathepsin B and L, respectively Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Sequence 4-Fluorophenylsulfonyl-Val-Leu-CHO Reconstitution Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 3 months at -20°C. Other Notes Inoue, J., et al. 2003. J. Med. Chem.46, 868. Tamada, Y., et al. 2001. Curr. Eye Res.22, 280. Mathur, P., et al. 2000. Curr. Eye Res.21, 926. Nath, R., et al. 2000. Biochem. Biophys. Res. Commun.274, 16. Tamada, Y., et al. 2000. J. Ocul. Pharmacol. Ther.16, 271. Fukiage, C., et al. 1998. Curr. Eye Res.17, 623. Fukiage, C., et al. 1997. Biochim. Biophys. Acta 1361, 304. Legal Information Sold under license of U.S. Patent 6,551,999